Lassa Virus Infection

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

United Therapeutics
United TherapeuticsMD - Silver Spring
1 program
1
ARN-75039 oral capsulesPhase 11 trial
Active Trials
NCT05735249Completed94Est. Mar 2025
Harmony Biosciences
Harmony BiosciencesPLYMOUTH MEETING, PA
1 program
1
MV-LASVPhase 11 trial
Active Trials
NCT04055454CompletedEst. Jan 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
United TherapeuticsARN-75039 oral capsules
Harmony BiosciencesMV-LASV

Clinical Trials (2)

Total enrollment: 94 patients across 2 trials

NCT05735249United TherapeuticsARN-75039 oral capsules

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects

Start: Jan 2023Est. completion: Mar 202594 patients
Phase 1Completed

A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)

Start: Sep 2019Est. completion: Jan 2021
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space